Human Genome Epidemiology Literature Finder
Records 1 - 25 (of 25 Records) |
Query Trace: Syndrome and DPYD[original query] |
---|
[Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance]. Zentralblatt für Gynäkologie 2002 Dec 124 (12): 574-9. Gross E, Seck K, Kiechle |
Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Annals of clinical biochemistry 2003 1 40 (Pt 1): 41-5. van Kuilenburg André B P, De Abreu Ronney A, van Gennip Albert |
Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer chemotherapy and pharmacology 2004 May 53 (5): 445-51. Hsiao Hui-Hua, Yang Ming-Yu, Chang Jan-Gowth, Liu Yi-Chang, Liu Ta-Chih, Chang Chao-Sung, Chen Tyen-Po, Lin Sheng-Fu |
Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population. Comptes rendus biologies 2007 Oct 330 (10): 764-9. Ben Fredj Radhia, Gross Eva, Chouchen Lotfi, B'Chir Fatma, Ben Ahmed Slim, Neubauer Steffi, Kiechle Marion, Saguem Sa |
The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer chemotherapy and pharmacology 2010 Jan 65 (2): 403-6. Loganayagam Aathavan, Arenas-Hernandez Monica, Fairbanks Lynette, Ross Paul, Sanderson Jeremy D, Marinaki Anthony |
Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clinical pharmacokinetics 2012 Mar 51 (3): 163-74. van Kuilenburg André B P, Häusler Peter, Schalhorn Andreas, Tanck Michael W T, Proost Johannes H, Terborg Christoph, Behnke Detlev, Schwabe Wolfgang, Jabschinsky Kati, Maring Jan Gera |
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. British journal of cancer 2013 Jun 108 (12): 2505-15. Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis C M, Harper P, Maisey N, Ross P, Sanderson J D, Marinaki A |
Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD. Cancer genomics & proteomics 0 10 (2): 89-92. Saif Muhammad Was |
[Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients]. Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 38 (4): 283-90. Cortejoso L, García M I, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L |
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut 2015 Jan 64 (1): 111-20. Rosmarin Dan, Palles Claire, Pagnamenta Alistair, Kaur Kulvinder, Pita Guillermo, Martin Miguel, Domingo Enric, Jones Angela, Howarth Kimberley, Freeman-Mills Luke, Johnstone Elaine, Wang Haitao, Love Sharon, Scudder Claire, Julier Patrick, Fernández-Rozadilla Ceres, Ruiz-Ponte Clara, Carracedo Angel, Castellvi-Bel Sergi, Castells Antoni, Gonzalez-Neira Anna, Taylor Jenny, Kerr Rachel, Kerr David, Tomlinson I |
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer chemotherapy and pharmacology 2015 Apr 75 (4): 763-72. Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny T D, Beijnen J H, Schellens J H |
Correlation analysis of peripheral DPYD gene polymorphism with 5-fluorouracil susceptibility and side effects in colon cancer patients. International journal of clinical and experimental medicine 2014 7 (12): 5857-61. Sun Wenhui, Yan Chungen, Jia Shaochang, Hu Jianh |
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. The Lancet. Oncology 2015 Oct . Meulendijks Didier, Henricks Linda M, Sonke Gabe S, Deenen Maarten J, Froehlich Tanja K, Amstutz Ursula, Largiadèr Carlo R, Jennings Barbara A, Marinaki Anthony M, Sanderson Jeremy D, Kleibl Zdenek, Kleiblova Petra, Schwab Matthias, Zanger Ulrich M, Palles Claire, Tomlinson Ian, Gross Eva, van Kuilenburg André B P, Punt Cornelis J A, Koopman Miriam, Beijnen Jos H, Cats Annemieke, Schellens Jan H |
Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. European journal of clinical pharmacology 2016 Nov . Roberto Michela, Romiti Adriana, Botticelli Andrea, Mazzuca Federica, Lionetto Luana, Gentile Giovanna, Paris Ida, Falcone Rosa, Bassanelli Maria, Di Pietro Francesca Romana, Onesti Concetta Elisa, Anselmi Elisabetta, Macrini Serena, Simmaco Maurizio, Marchetti Pao |
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial. JAMA oncology 2017 Jul . Yap Yoon-Sim, Kwok Li-Lian, Syn Nicholas, Chay Wen Yee, Chia John Whay Kuang, Tham Chee Kian, Wong Nan Soon, Lo Soo Kien, Dent Rebecca Alexandra, Tan Sili, Mok Zuan Yu, Koh King Xin, Toh Han Chong, Koo Wen Hsin, Loh Marie, Ng Raymond Chee Hui, Choo Su Pin, Soong Richie Chuan Te |
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. European journal of cancer (Oxford, England : 1990) 2018 8 102 31-39. Madi Ayman, Fisher David, Maughan Timothy S, Colley James P, Meade Angela M, Maynard Julie, Humphreys Vikki, Wasan Harpreet, Adams Richard A, Idziaszczyk Shelley, Harris Rebecca, Kaplan Richard S, Cheadle Jeremy |
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. European journal of human genetics : EJHG 2019 11 28 (4): 508-517. Lunenburg Carin A T C, van der Wouden Cathelijne H, Nijenhuis Marga, Crommentuijn-van Rhenen Mandy H, de Boer-Veger Nienke J, Buunk Anne Marie, Houwink Elisa J F, Mulder Hans, Rongen Gerard A, van Schaik Ron H N, van der Weide Jan, Wilffert Bob, Deneer Vera H M, Swen Jesse J, Guchelaar Henk-J |
Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin. Drug metabolism and personalized therapy 2020 9 35 (4): . Varma Ashok, Jayanthi Mathaiyan, Dubashi Biswajit, Shewade Deepak Gopal, Sundaram Raj |
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy. Frontiers in oncology 2020 8 10 1155. Bruera Gemma, D'Andrilli Antonio, Simmaco Maurizio, Guadagni Stefano, Rendina Erino Angelo, Ricevuto Enri |
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast cancer research and treatment 2020 May . O'Donnell Peter H, Trubetskoy Vassily, Nurhussein-Patterson Ashley, Hall Julianne P, Nath Aritro, Huo Dezheng, Fleming Gini F, Ingle James N, Abramson Vandana G, Morrow P K, Storniolo Anna Maria, Forero Andres, Van Poznak Catherine, Liu Minetta C, Chang Jenny C, Merkel Douglas E, Peppercorn Jeffrey M, Rugo Hope S, Dees E Claire, Hahn Olwen M, Hoffman Philip C, Rosner Gary L, Huang R Stephanie, Ratain Mark J, Cox Nancy, Olopade Olufunmilayo I, Wolff Antonio C, Dolan M Eileen, Nanda Rita, |
Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study. BMC medicine 2020 11 18 (1): 367. Turner R M, de Koning E M, Fontana V, Thompson A, Pirmohamed |
Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis. The oncologist 2021 9 26 (12): 1008-1016. Sharma Bhavina B, Rai Karan, Blunt Heather, Zhao Wenyan, Tosteson Tor D, Brooks Gabriel |
Exome sequencing in BRCA1-2 candidate familias: the contribution of other cancer susceptibility genes. Frontiers in oncology 2021 11 649435. Doddato Gabriella, Valentino Floriana, Giliberti Annarita, Papa Filomena Tiziana, Tita Rossella, Bruno Lucia Pia, Resciniti Sara, Fallerini Chiara, Benetti Elisa, Palmieri Maria, Mencarelli Maria Antonietta, Fabbiani Alessandra, Bruttini Mirella, Orrico Alfredo, Baldassarri Margherita, Fava Francesca, Lopergolo Diego, Lo Rizzo Caterina, Lamacchia Vittoria, Mannucci Sara, Pinto Anna Maria, Curr Aurora, Mancini Virginia, , , Mari Francesca, Renieri Alessandra, Ariani Frances |
Concomitant Administration of Capecitabine and Folate Supplements: Need to Encourage Medication Reconciliation. Pharmaceuticals (Basel, Switzerland) 2022 11 15 (11): . Stefanelli Berenice, Sellitto Carmine, De Bellis Emanuela, Torsiello Martina, Bertini Nicola, Pezzullo Angelo Maria, Corbi Graziamaria, Sabbatino Francesco, Pepe Stefano, Tesse Angela, Conti Valeria, Filippelli Amel |
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 1 159 114232. de With Mirjam, van Doorn Leni, Maasland Demi C, Mulder Tessa A M, Oomen-de Hoop Esther, Mostert Bianca, Homs Marjolein Y V, El Bouazzaoui Samira, Mathijssen Ron H J, van Schaik Ron H N, Bins Sand |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: